title: Allogeneic-blood stem-cell collection following mobilization with low-dose granulocyte colony-stimulating factor.
abstract: OBJECTIVE
  The optimal dose of granulocyte colony-stimulating factor (G-CSF) for mobilization of allogeneic-blood stem cells (AlloBSC) has yet to be determined. As part of a prospective trial, 41 related human leukocyte antigen (HLA)-matched donors had blood cells mobilized with G-CSF at 5 micrograms/kg/d by subcutaneous administration. The purpose of this trial was to monitor adverse effects during G-CSF administration and stem-cell collection, to determine the optimal timing for stem-cell collection, and to determine the cellular composition of stem-cell products following G-CSF administration.
  
  
  METHODS
  The median donor age was 42 years. Apheresis began on day 4 of G-CSF administration. At least three daily 12-L apheresis collections were performed on each donor. A minimum of 1.0 x 10(6) CD34+ cells/kg (recipient weight) and 8.0 x 10(8) mononuclear cells/kg were collected from each donor. All collections were cryopreserved in 5% dimethyl sulfoxide and 6% hydroxyethyl starch.
  
  
  RESULTS
  Toxicities associated with G-CSF administration and the apheresis process included myalgias/arthralgias (83%), headache (44%), fever (27%), and chills (22%). The median baseline platelet count of 242 x 10(4)/ mL decreased to 221, 155, and 119 x 10(6)/mL on days 4, 5, and 6 of G-CSF administration, respectively. Median numbers of CD34+ cells in collections 1, 2, and 3 were 1.99, 2.52, and 3.13 x 10(6)/kg, respectively. The percentage and total number of CD4+, CD8+, and CD56+/CD3- cells remained relatively constant during the three collections. Median total numbers of cells were as follows: CD34+, 7.73 x 10(6)/kg; and lymphocytes, 6.93 x 10(8)/kg.
  
  
  CONCLUSIONS
  Relatively low doses of G-CSF can mobilize sufficient numbers of AlloBSC safely and efficiently.
authors.affiliation: Department of Internal Medicine, University of Nebraska Medical Center, Omaha 68198-3330, USA. MRBishop@mail.UNMC.edu
authors.forename: M R
authors.initials: MR
authors.lastname: Bishop
authors.forename: S R
authors.initials: SR
authors.lastname: Tarantolo
authors.forename: J D
authors.initials: JD
authors.lastname: Jackson
authors.forename: J R
authors.initials: JR
authors.lastname: Anderson
authors.forename: K
authors.initials: K
authors.lastname: Schmit-Pokorny
authors.forename: D
authors.initials: D
authors.lastname: Zacharias
authors.forename: Z S
authors.initials: ZS
authors.lastname: Pavletic
authors.forename: S J
authors.initials: SJ
authors.lastname: Pirruccello
authors.forename: J M
authors.initials: JM
authors.lastname: Vose
authors.forename: P J
authors.initials: PJ
authors.lastname: Bierman
authors.forename: P I
authors.initials: PI
authors.lastname: Warkentin
authors.forename: J O
authors.initials: JO
authors.lastname: Armitage
authors.forename: A
authors.initials: A
authors.lastname: Kessinger
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014019:Tissue Donors; D014184:Transplantation, Homologous
chemical_list: D016179:Granulocyte Colony-Stimulating Factor